ERO1A and neoplasm: Considering data showing that ERO1A is not a statistically significant independent marker of prediction of response to Osimertinib treatment it is likely that additional understanding of downstream dependency or phramcodynamic markers will be required to predict sensitivity to inhibition of ERO1A activity as a single agent or in combination with Osimertinib with respect to tumor response.